EXOMIND

Overview

EXOMIND is BTL Industries' entry in the TMS category, built on patented ExoTMS technology that stimulates the dorsolateral prefrontal cortex. Each session runs under 30 minutes, and the FDA-cleared depression protocol is 6 sessions, a fraction of the 20-36 sessions a traditional TMS course requires. FDA cleared in 2024, it lists at $100,000-$200,000 for new units. The used market is thin because the device is so new and early owners are not reselling.

EXOMIND is FDA-cleared for depression. BTL also holds Health Canada and CE clearances for anxiety symptoms, obsessive-compulsive disorder, and excessive eating disorders, though those indications are not FDA-cleared in the US. The short six-session protocol is the device's main differentiator against established TMS platforms. Where it fits in your practice depends on patient demand, treatment volume, and whether you want the BTL brand and support behind a still-emerging device.

EXOMIND is manufactured by BTL Industries (Prague, Czech Republic, founded 1993). The device benefits from BTL Industries' long manufacturer history and presence across 90+ countries. Service support, training availability, and parts access vary by region. Practices considering this device should validate dealer presence and technical support coverage in their area before signing a contract.

Pros & Cons

Clinical Evidence

Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing. The published evidence base for EXOMIND reflects how long the platform has been in market and how much the manufacturer has invested in clinical research. Devices with FDA clearance dates before 2018 typically have stronger peer-reviewed datasets than newer entrants. For physicians evaluating this device, the questions worth asking are whether the studies used blinded evaluators, what the sample sizes were, and whether the research was independent or manufacturer-funded.

Compare EXOMIND's evidence base against the category benchmark. In EXOMIND's category, the strongest evidence typically comes from devices that have been on the market for at least five years and have multiple randomized controlled trials with independent funding. Marketing claims from any manufacturer should be cross-checked against PubMed-indexed publications rather than conference posters or white papers. Conference presentations are not equivalent to peer review.

For practices that require strong clinical evidence (academic dermatology, plastic surgery groups with research interests, multi-physician practices that need to defend purchase decisions internally), the evidence profile should be a top-three decision factor. For high-volume cash-pay practices where patient demand drives device selection, brand recognition often matters more than the underlying evidence base. Both approaches are defensible, but they lead to different device selections.

ROI Analysis

Practice ROI for EXOMIND depends on three variables: capital cost, per-session revenue, and treatment volume. At a new unit price of $100,000-$200,000, financed over five years at typical equipment rates, the monthly payment runs roughly 2-2.5% of total cost. With patients paying $400-$600 per session and no per-treatment consumables, gross margin per session is high; the device just needs to fill enough slots to cover the payment, the service contract, and operator labor.

For a practice running 2-3 patients per day at the midpoint of the per-session range, EXOMIND typically reaches break-even at 12-18 months for the lower end of the new pricing range, or 18-30 months at the high end. Because the used market is thin, there is no cheap secondary unit to shortcut payback, so the math has to work on a new purchase. The biggest practice mistake is over-projecting treatment volume. Physicians who run their numbers on 4-6 daily treatments rarely hit those targets in year one.

The realistic question is not whether EXOMIND can pay back. Most devices in this price range do, eventually. The question is whether your practice can fill the schedule. Practices with existing patient flow in Psychiatry, Neurology have the easiest path. Practices building demand from scratch should plan for 6-12 months of marketing investment before the device pays for itself.

Best For

Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage. The fit is strongest for practices that match the device's positioning on price, clinical evidence requirements, and patient throughput expectations. Practices with mismatched economics often regret these purchases within 18 months.

Beyond practice type, EXOMIND fits best when the patient base aligns with the device's strengths. For a TMS platform, that means a steady flow of depression patients who prefer a drug-free option and can pay cash, since there is no established US insurance pathway for EXOMIND yet. Practices already running BTL aesthetic devices have a natural cross-sell into the same patient base. Practices building demand from scratch should budget marketing time before the schedule fills.

Buying Guide

New EXOMIND units sell for $100,000-$200,000 from BTL Industries or authorized reps. There is little used inventory because the device only reached the US market in 2024, so most buyers are purchasing new. A new unit includes a 12-24 month warranty, current software, the ExoTMS coil, and training. The practical decision is not new versus used; it is how hard you negotiate the new deal and the service terms that follow it.

What to negotiate: extended warranty and a written post-warranty service price, the coil and any spare components included rather than billed separately, training and certification fees, marketing and launch support, and bundle pricing if you already run BTL aesthetic devices. BTL reps typically have 10-15% list price flexibility and more on bundled deals. End-of-quarter and end-of-year are the strongest negotiation windows.

What to watch for: per-treatment or per-indication software licensing fees that do not show up in the headline price, and service contract terms after the warranty lapses. Always require a written quote that breaks out the console, coil, training, and first-year service separately. Bundled quotes hide the line items where margins live.

EXOMIND Machine Cost: What a Unit Runs in 2026

An EXOMIND machine costs $100,000 to $200,000 new from BTL. That is the capital price for the console and ExoTMS coil, before training, service, or any bundle pricing. BTL cleared EXOMIND with the FDA for depression in 2024, so the device is new and the secondary market is thin. There is no meaningful used pricing yet because owners are not reselling units this early. Per-session, consumable, and annual maintenance pricing have not stabilized publicly, which is common for a device in its first two years on the US market. Ask BTL for a written quote that breaks out the console, coil, training, and first-year service, and ask specifically about any per-session or software fees that do not show up in the headline number.

Here is how EXOMIND's cost sits against the established TMS systems it competes with:

EXOMIND carries the highest capital cost of the group. The 6-session protocol is the reason BTL prices it at a premium. Where NeuroStar or MagVenture cost less up front, they require 30-plus sessions per patient. EXOMIND's pitch is that the same chair can treat far more patients per month, so the higher machine cost spreads across more treatment courses.

The 6-Session Math: Why Cost Per Chair Matters More Than Sticker Price

EXOMIND's economics hinge on throughput, not the sticker. A standard NeuroStar practice runs a patient through 36 sessions over six weeks. EXOMIND clears a course in 6 sessions. In theory, one chair can cycle through six times as many patients in the same window. Revenue per patient is lower because the course is shorter, but revenue per chair-hour can be higher if you keep the schedule full.

The catch is filling the schedule. The throughput advantage only pays off with a deep referral pipeline. A practice doing 2-3 standard TMS patients a day generates roughly the same revenue as a practice running 12-15 EXOMIND patients a day. Most psychiatry practices in mid-sized markets struggle to keep even 2-3 TMS chairs full. Before you buy at $100,000 to $200,000, run the chair-fill math on your actual referral volume, not BTL's best-case projection.

Financing, Section 179, and the BTL Bundle

Most buyers finance EXOMIND over five years at equipment rates, which puts the monthly payment near 2% to 2.5% of the purchase price. On a $150,000 unit, that is roughly $3,000 to $3,750 a month before consumables and labor. EXOMIND qualifies for Section 179 expensing, so a practice can deduct the full purchase price in the year it goes into service. On a $150,000 unit, a practice in a 32% bracket recovers about $48,000 through the deduction, dropping the effective cost toward $102,000. Confirm current Section 179 limits with your accountant.

The BTL bundle is the wildcard on cost. If your practice already runs BTL aesthetic devices (Emsella, Emsculpt Neo), BTL's sales team often packages EXOMIND pricing into a larger equipment deal, which can cut the effective capital cost. Practices with no existing BTL relationship pay closer to the full list. That bundling dynamic is the single biggest reason two practices see different EXOMIND machine costs for the same configuration. For the head-to-head economics, see the NeuroStar vs EXOMIND comparison and the BrainsWay vs EXOMIND comparison.

Is EXOMIND FDA Approved?

EXOMIND is FDA cleared, not FDA approved, and the distinction matters when you field patient questions. BTL received 510(k) clearance for EXOMIND in 2024 for the treatment of depression. Clearance means the FDA agreed the device is substantially equivalent to TMS systems already on the market, the same regulatory path NeuroStar and BrainsWay took. It is not the premarket approval (PMA) standard used for high-risk implants. For a depression device, 510(k) clearance is the normal and expected pathway. In Canada and the EU, BTL also markets EXOMIND for anxiety, OCD, and binge eating, but those indications are not cleared in the US as of 2026. Tell patients it is FDA cleared for depression and be precise about which claims apply in which country.

Is EXOMIND Safe? Side Effects to Expect

EXOMIND uses the same external transcranial magnetic stimulation principle as every other TMS device, so its safety profile tracks the established TMS category rather than something new. The common side effects are the ones psychiatrists already counsel for: scalp discomfort or a tapping sensation at the treatment site, transient headache, and lightheadedness right after a session. These are usually mild and fade within the first week of treatment. The serious risk across all TMS systems is seizure, which is rare and tied to specific contraindications such as a history of seizures, certain medications, or metal near the coil. Because EXOMIND is new, its long-term real-world safety record is shorter than NeuroStar's decade-plus of data. Screen patients against standard TMS contraindications and the device behaves like the category it belongs to.

EXOMIND Reviews: What Early Adopters Report

Published, peer-reviewed EXOMIND outcome data is still thin because the device is new to the US market. Most of what circulates online is BTL marketing material or early-adopter practice anecdotes, not independent clinical trials. The recurring themes from practices running it: patients prefer the 6-session commitment over a six-week daily course, and BTL's service and training are responsive. The recurring caution: pricing is high and not yet standardized, and the evidence base is not where NeuroStar's is. Treat current EXOMIND reviews as directional, not conclusive. For hard efficacy comparison, weigh it against the deeper trial record behind NeuroStar and BrainsWay before committing.

EXOMIND vs Traditional TMS

The core difference is the protocol, not the physics. Traditional TMS (NeuroStar, BrainsWay, MagVenture) runs 20 to 36 sessions over four to six weeks, with strong insurance reimbursement and a long published evidence base. EXOMIND compresses the course to 6 sessions, which is its entire pitch: less patient time and faster chair turnover. The tradeoffs are real. Traditional TMS has established CPT reimbursement and years of outcome data; EXOMIND has neither yet, so most EXOMIND treatment today is cash-pay. If your priority is insurance-covered treatment with the deepest evidence, traditional TMS still wins. If your priority is throughput and a shorter course for cash-pay patients, EXOMIND's 6-session model is the reason to look.

Alternatives and Comparisons

The main alternatives to EXOMIND in this category are listed below. Click into any comparison for a full side-by-side breakdown.